The UK and US have established a landmark commercial pact that will ensure zero levies on UK medicine products going into the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase spending on medicines through the NHS. This commitment secures that import taxes on these crucial goods will stay at nothing for a timeframe of 36 months.
This agreement comes after recent threats to hike duties on branded pharmaceutical products, with figures floated reaching 100%.
"This agreement with the Britain bolsters the worldwide climate for cutting-edge drugs and establishes much-needed equity to American-British drug exports," a release said.
Trade Impact
Drugs are one of the the United Kingdom's biggest exports to the America, which is by far the biggest buyer for leading companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months prior to September, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This value made up 17.4% of all goods exports in that period.
"This deal secures employment, increases funding and sets the stage for the UK to emerge as a international leader for medical research," the Business and Trade Secretary commented.
Specific British Pledges
The pact includes several key pledges from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to increase total health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. In the past, rebates topped twenty percent.
Broader Context
This agreement takes place against a ongoing tension between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
This friction were heightened by claims that American consumers were paying several times more for the same drugs than patients in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been paused or abandoned, while major investments have been announced toward American operations.
One official stated that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
